Cargando…

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2

CoronaVac, also known as the Sinovac inactivated SARS-CoV-2 vaccine, has been widely implemented in combating the COVID-19 pandemic. We summarized the results of clinical trials and real-world studies of CoronaVac in this review. The overall efficacy for the prevention of symptomatic COVID-19 (befor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Lairun, Li, Zhuopei, Zhang, Xiaoyin, Li, Jingxin, Zhu, Fengcai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronavirus – Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746539/ https://www.ncbi.nlm.nih.gov/pubmed/35878789 http://dx.doi.org/10.1080/21645515.2022.2096970

Ejemplares similares

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
por: Jin, Lairun, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022)

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
por: Zhang, Xiaoyin, et al.
Publicado: (2023)

Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial
por: Zhu, Dandan, et al.
Publicado: (2022)

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
por: Bayhan, Gulsum Iclal, et al.
Publicado: (2022)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
por: Fernandes, Eder Gatti, et al.
Publicado: (2021)

A preliminary study on the effectiveness of maternal to neonatal transfer of antibodies against SARS-CoV-2 in the women vaccinated with heterologous CoronaVac–ChAdOx1
por: Pongsatha, Saipin, et al.
Publicado: (2023)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study
por: Cao, Cheng, et al.
Publicado: (2023)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)

Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions
por: Li, Chunmei, et al.
Publicado: (2022)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac)
por: Jiang, Zhujun, et al.
Publicado: (2022)

CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021)

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
por: Karacin, Cengiz, et al.
Publicado: (2021)

Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
por: Netto, Lucas C, et al.
Publicado: (2022)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival
por: Sevinc, Sultan Acar, et al.
Publicado: (2022)

Unilateral Axillary Lymphadenopathy after the Inactivated SARS-COV-2 (CoronaVac) Vaccine: Ultrasonographic Imaging
por: Elverici, Eda, et al.
Publicado: (2023)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
por: Soysal, Ahmet, et al.
Publicado: (2021)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

CoronaVac efficacy data from Turkey – Authors' reply
por: Tanriover, Mine Durusu, et al.
Publicado: (2021)

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
por: Han, Bihua, et al.
Publicado: (2021)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

CoronaVac: more data for regulators and policy makers
por: Ramasamy, Maheshi N, et al.
Publicado: (2021)

Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

Humoral Immune Response to CoronaVac in Turkish Adults
por: Cosgun, Yasemin, et al.
Publicado: (2023)

ANCA-associated vasculitis following the CoronaVac vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0vllqmcpemnghncm9jromdfcml